QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 invo-fertility-stock-is-plunging-after-white-house-announcement

INVO Fertility Inc (NASDAQ:IVF) shares are trading lower on Thursday as investors book profits following White House announceme...

 uk-health-agency-recommends-gsk-backed-viiv-healthcares-apretude-as-injectable-hiv-treatment

NICE recommends ViiV Healthcare's Apretude as the first injectable PrEP for HIV prevention, offering an alternative to dail...

 novo-vs-lilly-vs-pfizer-who-wins-if-trump-slashes-the-price-of-weight-loss-drugs

Trump's promise to cut cost of Novo Nordisk A/S drug Ozempic from $1,300 to $150 shakes GLP-1 gold rush, with potential imp...

 reported-earlier-pfizer-ceo-says-us-pharma-industry-needs-to-collaborate-with-china--reuters

https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-ceo-says-us-pharma-industry-needs-collaborate-with-china-202...

 pfizer-seeks-expanded-use-approval-for-breast-cancer-drug

Pfizer's Tukysa improved progression-free survival in first-line HER2+ metastatic breast cancer, showing strong efficacy an...

 hedge-fund-shah-capital-urges-novavax-to-consider-sale-amid-vaccine-rollout-struggles-sees-5-billion-potential

Shah Capital urges Novavax to consider a sale after poor COVID-19 vaccine rollout, highlighting the potential value of at least...

 pfizer-announces-topline-results-from-phase-3-her2climb-05-trial-of-first-line-combination-therapy-with-tyrosine-kinase-inhibitor-tukysa-in-patients-with-her2-mbc

Pfizer Inc. (NYSE:PFE) today announced positive topline results from the Phase 3 HER2CLIMB-05 trial of first-line combination t...

Core News & Articles

Presentation to include new patient-reported outcomes (PRO) data from the Phase 3 VERITAC-2 clinical trial 

 pfizer-to-present-46-infectious-disease-abstracts-at-idweek-2025-congress-highlighting-advancements-in-prevention-and-treatment

Pfizer Inc. (NYSE:PFE, "Pfizer"))) will present data across its infectious disease portfolio at the upcoming IDWeek 202...

Core News & Articles

https://www.youtube.com/watch?v=XOtOCzut9pM

 trump-plans-astrazeneca-deal-to-cut-drug-prices-for-low-income-americans

Trump to announce new deal with AstraZeneca to lower prescription drug costs for Americans using most-favored-nation pricing mo...

 morgan-stanley-maintains-equal-weight-on-pfizer-lowers-price-target-to-32

Morgan Stanley analyst Terence Flynn maintains Pfizer (NYSE:PFE) with a Equal-Weight and lowers the price target from $33 to...

 trump-administration-engages-pharmacies-goodrx-for-trumprx-launch

Pharmacies and GoodRx are in talks to join TrumpRx, a new drug pricing site aiming to lower prescription costs for U.S. consumers.

 amgen-to-offer-cholesterol-drug-at-60-discount-as-trump-administrations-call-to-lower-drug-prices

Amgen launches AmgenNow, offering Repatha at $239 per month, expanding direct access for U.S. patients with no insurer restrict...

 wall-street-hits-record-highs-as-rate-cut-bets-offset-shutdown-this-week-in-markets

S&P500, Nasdaq100, Dow Jones, and Russell 2000 all hit record highs as investors focus on corporate optimism, monetary easi...

 b-of-a-securities-maintains-neutral-on-pfizer-raises-price-target-to-30

B of A Securities analyst Tim Anderson maintains Pfizer (NYSE:PFE) with a Neutral and raises the price target from $28 to $30.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION